Before a Protocol Opens: What a Clinical Trial Feasibility and Site Selection Specialist Does

Introduction

Long before a patient signs a consent form, a clinical trial has already passed through a quieter gate: someone has decided which countries, which hospitals or clinics, and which investigators are realistically capable of running it. That decision shapes everything downstream - enrollment speed, data quality, and whether the trial hits its timeline at all - and it belongs to feasibility and site selection, a specialty that sits at the front end of clinical operations and rarely gets the attention monitoring or data management do. A feasibility and site selection specialist is the person who turns a protocol's requirements into a realistic plan for where and how the study can actually be conducted.

What Feasibility Work Actually Involves

Feasibility starts with the protocol itself. A specialist reads the inclusion and exclusion criteria, the visit schedule, the required procedures and equipment, and translates that into a question: given this design, which patient populations, countries, and sites could plausibly deliver the enrollment numbers on the timeline the sponsor needs? That's not a guess. It usually draws on epidemiological data about disease prevalence in different regions, competing trials recruiting from the same patient pool, prior enrollment performance at candidate sites, and increasingly, electronic health record or claims data that estimates how many eligible patients a given health system actually sees.

The output is typically a feasibility assessment or country and site recommendation that goes to the sponsor's clinical operations leadership before a single site is approached. It might rule out a country entirely because standard-of-care treatment there conflicts with the trial design, or flag that a rare-disease protocol needs twice as many sites as a common-condition trial to hit the same enrollment target. Getting this wrong is expensive - a trial that's under-enrolled six months in usually traces back to an optimistic feasibility assessment that didn't account for competing studies or an unrealistic read of how many patients actually meet strict eligibility criteria.

From Assessment to Site Selection

Once the feasibility picture narrows the field, site selection specialists evaluate specific investigators and institutions. This usually starts with a site feasibility questionnaire sent to candidate sites, asking about patient volume for the relevant condition, prior trial experience, staffing, available equipment, and regulatory or ethics committee timelines in that jurisdiction. Responses get verified, not just collected - an investigator's self-reported patient volume often doesn't match what a closer look at referral patterns or prior enrollment history shows.

Site selection visits, whether in person or remote, are where a specialist assesses things a questionnaire can't capture: whether the site's coordinator team seems organized, whether the facility has the freezer capacity or imaging equipment the protocol requires, whether the investigator is genuinely engaged or delegating everything to a research team stretched across too many concurrent studies. A site that looks excellent on paper can fail this part of the evaluation, and a specialist's job is to catch that before the site is contracted, not after enrollment stalls.

Working With Data, Not Just Relationships

Feasibility used to lean heavily on institutional memory - operations teams who simply knew which sites performed well on past trials. That still matters, but the field has moved toward more systematic data use. Many sponsors and CROs now maintain site performance databases tracking metrics like screen failure rates, time to first patient enrolled, and protocol deviation rates across prior studies, and a feasibility specialist draws on that history rather than relying purely on relationships. Real-world data sources, including de-identified claims data and health system registries, are increasingly used to model patient availability before a single site conversation happens, which has made early feasibility assessments considerably more rigorous than they were even a decade ago.

That said, the role hasn't become purely quantitative. Reading whether a site's enthusiasm in a feasibility call is backed by actual operational capacity is still a judgment call, built from experience watching which promising sites deliver and which don't. The best feasibility specialists combine comfort with data analysis and a practiced skepticism about what sites say they can do versus what they've actually done before.

Where Feasibility Sits in the Organization

At sponsor companies, feasibility and site selection is usually part of a broader clinical operations function, sometimes as a dedicated team and sometimes as a responsibility split across clinical trial managers and study start-up specialists. Contract research organizations frequently run dedicated feasibility departments that serve multiple sponsor clients, giving specialists there broader exposure across therapeutic areas and geographies than an in-house role typically offers. Some larger sites and site networks have built their own feasibility functions in reverse - evaluating which incoming trial opportunities are worth pursuing given their own patient population and capacity, a smaller but growing mirror image of the sponsor-side role.

The function also intersects closely with study start-up, the team responsible for turning a selected site into an activated one through contracting, budget negotiation, and ethics committee approval. In many organizations these are separate roles with a handoff between them; in smaller ones, a single person may carry a site from initial feasibility assessment through to activation.

Skills That Separate a Strong Specialist

Protocol literacy is the baseline - the ability to read a complex protocol and immediately identify what it will demand operationally, before a site ever sees it. Beyond that, the role rewards comfort with data tools, since country and site modeling increasingly happens in spreadsheets or dedicated feasibility software rather than through pure relationship knowledge. Communication matters just as much: a specialist has to extract honest answers from investigators and coordinators who have an incentive to present their site favorably, which takes a mix of structured questioning and the ability to read between the lines of an enthusiastic but vague response.

Therapeutic area knowledge helps considerably, since feasibility for an oncology trial with narrow biomarker-driven eligibility looks very different from feasibility for a primary-care cardiovascular study. Many specialists build that depth by staying within one or two therapeutic areas over several years rather than moving broadly across them, trading breadth for the kind of pattern recognition that makes a feasibility assessment genuinely predictive rather than a best guess dressed up in a template.

Working Across Borders and Regulatory Environments

Most trials of any meaningful size run across multiple countries, which means a feasibility specialist has to weigh more than patient volume and site capability. Different countries have different ethics committee and institutional review board timelines, different requirements for importing investigational product, and sometimes different standard-of-care treatments that can make a protocol's control arm impractical or even unethical in a given setting. A country that looks attractive purely on patient numbers can turn out to add months to a trial's start-up timeline once local regulatory and ethics review realities are factored in, so feasibility assessments increasingly build in a realistic start-up timeline estimate per country rather than treating enrollment potential as the only variable that matters.

Language and cultural factors play into site-level assessments too, particularly for trials with patient-reported outcome measures that need to be properly translated and validated for each population, or recruitment strategies that have to account for how patients in a given region typically learn about and decide to join a clinical trial. A specialist working across several regions regularly has to balance a sponsor's preference for a small number of high-enrolling countries against the operational and regulatory complexity each additional country introduces, and that trade-off is as much a judgment call as a data-driven calculation.

How People Get Into This Work

Entry paths vary more than in some clinical operations roles. Some specialists move in from clinical research coordinator or clinical research associate positions, bringing direct knowledge of what a site visit and site relationship actually involve. Others come from a more analytical background - health economics, epidemiology, or data analysis roles - and build clinical operations knowledge on top of existing comfort with the data work feasibility increasingly requires. A smaller number move over from study start-up or site contracting, drawn by the earlier, more strategic point in the trial lifecycle where feasibility operates.

There's no single certification that defines the field the way RAC does for regulatory affairs, though training through organizations like the Association of Clinical Research Professionals or the Society for Clinical Research Sites can build relevant background. Most hiring managers weigh direct exposure to site operations or data analysis more heavily than formal credentials, especially for specialists moving in from adjacent clinical research roles.

Career Trajectory

Early roles typically involve supporting a senior feasibility lead with questionnaire administration, data gathering, and site visit coordination before taking ownership of country or site recommendations independently. From there, the path usually moves toward leading feasibility for larger, more complex trials, then into a strategic feasibility or site intelligence leadership role overseeing a portfolio of studies and the data infrastructure that supports them. Some specialists move laterally into study start-up or broader clinical operations management, using feasibility as a foundation for a wider clinical trial management career rather than a narrow specialty.

Conclusion

Feasibility and site selection rarely shows up in a trial's public story - nobody writes press releases about a well-chosen site list - but the decisions made here largely determine whether a trial finishes on time with usable data or drags through repeated enrollment extensions. For clinical professionals who find strategic, upstream problem-solving more interesting than the day-to-day of site monitoring, it's a career path that puts real analytical and judgment skills to work before a protocol ever reaches a patient.